Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib

Hepatology Research

Volumn 44, Issue 12, 2014, Pages 1179-1185

  Terashima, Takeshi ^a   Yamashita, Tatsuya ^a   Arai, Kuniaki ^a   Sunagozaka, Hajime ^a   Kitahara, Masaaki ^a   Nakagawa, Hidetoshi ^a   Kagaya, Takashi ^a   Mizukoshi, Eishiro ^a   Honda, Masao ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Sorafenib

Indexed keywords

CISPLATIN; CREATININE; FLUOROURACIL; PEGINTERFERON ALPHA2B; SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTERY OCCLUSION; ARTICLE; ASCITES; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CATHETER OCCLUSION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HEPATIC ARTERY; HICCUP; HUMAN; HYPOKALEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; METASTASIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PANCYTOPENIA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMACH ULCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR INVASION; UNSPECIFIED SIDE EFFECT; VASCULITIS; VERY ELDERLY;

EID: 84914161467     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12266     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol 2012; 39: 399-409.
3. Song MJ, Chun HJ, Song S et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-50.
4. Tateishi R, Shiina S, Teratani T et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-9.
5. Takizawa D, Kakizaki S, Sohara N et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci 2007; 52: 3290-5.
6. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
7. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
8. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
9. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
10. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.
11. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-26.
12. Reed ML, Vaitkevicius VK, Al-Sarraf M et al. The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. Cancer 1981; 47: 402-9.
13. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5- fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685-93.
14. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-7.
15. Yamashita T, Arai K, Sunagozaka H et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 281-90.
16. Araki T, Itai Y, Furui S, Tasaka A. Dynamic CT densitometry of hepatic tumors. AJR Am J Roentgenol 1980; 135: 1037-43.
17. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 4th Japanese edn. Tokyo: Kanehara, 2000.
18. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 2nd English edn. Tokyo: Kanehara, 2003.
19. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
20. Reig M, Rimola J, Torres F et al. Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. Hepatology, 2013. doi: 10.1002/hep.26586
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
22. Kaneko S, Furuse J, Kudo M et al. Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcioma 2010 update. Hepatol Res 2012; 42: 523-42.
23. Morimoto M, Numata K, Kondo M et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res 2011; 41: 296-302.
24. Finn RS, Kang YK, Mulcahy M et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2090-8.
25. Santoro A, Rimassa L, Borbath I et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63.
26. Yau T, Wong H, Chan P et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenibrefractory disease. Invest New Drugs 2012; 30: 2384-90.
27. Katamura Y, Aikata H, Kimura Y et al. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. J Gastroenterol Hepatol 2010; 25: 1117-22.
28. Dhooge M, Coriat R, Mir O et al. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis. Oncology 2013; 84: 6-13.
29. Mir O, Coriat R, Boudou-Rouquette P et al. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Med Oncol 2012; 29: 2793-9.